Fresenius Acquires Full Control of mAbxience
Fresenius Kabi completed the purchase of its remaining 45 percent stake in the biosimilar developer on September 30, 2026.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you trust that larger pharmaceutical company mergers result in better access to affordable medications?
Fresenius acquired the remaining 45 percent stake in mAbxience from Insud Pharma S.L. and Invim Corporativo S.L. for up to 750 million euros, effective September 30, 2026. The company is now a wholly owned subsidiary of Fresenius Kabi.
Why it matters
Full ownership allows Fresenius to exert direct control over biosimilar manufacturing, investment strategies, and product launch timing. This consolidation is expected to provide immediate value by boosting the group core earnings per share.
The deal involves a total investment of up to 750 million euros, including a 50 million euro contingent payment for specific site approvals. Fresenius now fully manages a portfolio that includes four existing biosimilar products and eight candidates in development.
The players
Fresenius
Fresenius is a global healthcare group providing products and services for dialysis, hospitals, and outpatient treatment.
mAbxience
mAbxience is a biopharmaceutical company specializing in the development, production, and commercialization of biosimilar products.
Jurgen Van Broeck
Jurgen Van Broeck serves as the Chief Executive Officer of mAbxience.
Dr. Sang-Jin Pak
Dr. Sang-Jin Pak is a senior leader at Fresenius to whom the CEO of mAbxience reports.
The details
The transaction, which did not require regulatory approval, integrates mAbxience into the Fresenius Kabi Biopharma unit. CEO Jurgen Van Broeck will continue to lead the subsidiary, reporting to Dr. Sang-Jin Pak, while Fresenius scales its global biosimilar development and licensing capabilities.
Timeline
August 2022: Fresenius acquires an initial 55 percent stake in mAbxience.
September 30, 2026: The acquisition of the remaining stake is completed.
October 1, 2026: Fresenius officially announces the completed transaction.
Market Landscape
The acquisition reflects the broader industry move toward vertical integration as global pharmaceutical companies attempt to capture margins from the rise of biosimilar competition in the global pharmaceutical market. By securing full ownership, Fresenius positions itself to accelerate its development pipeline against other major biosimilar rivals.
This corporate consolidation typically aims to streamline manufacturing costs and shorten the timelines for bringing new biosimilar treatments to the global market. While the move impacts internal corporate structure, patients may eventually see expanded access to more affordable biosimilar versions of complex biologic drugs.
The takeaway
Full control of a subsidiary allows firms to streamline complex global R&D and manufacturing operations under a single strategic vision. Investors should monitor how the integration of the eight new biosimilar candidates affects future quarterly earnings reports.
Further reading
Learn more about industry shifts in the Healthcare sector.
Source note: This article includes information reported by Big Molecule Watch.
Live Poll
Do you trust that larger pharmaceutical company mergers result in better access to affordable medications?
